EnglishFrenchGermanItalianSpanish

WELCOME TO THE NEWSROOM

WATCH OUR LATEST VIDEO

Category: New Products

Ann Arbor, MI (July 23, 2019) – NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on central laboratory customers, announced today the launch of CE-IVD assays for Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV). Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) are herpes viruses found in up to 90% of the adult population.  Usually latent, the presence...

Ann Arbor, MI (June 21, 2019) – NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on central laboratory customers, announced today the launch of CE-IVD assays for Hepatitis B virus (HBV) and Hepatitis C virus (HCV). Hepatitis infections are more frequent in immunocompromised populations than in the general population with lower rates of spontaneous recovery...

Ann Arbor, Michigan (July 2018) – NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on central laboratory customers, announced today it has received FDA 510(k) clearance for its NeuMoDx™ 288 Molecular System and its NeuMoDx™ GBS Assay. The fully automated NeuMoDx™ 288 Molecular System is the first offering in a family of scalable platforms that integrate...

Ann Arbor, Michigan (July 1, 2018) – NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on central laboratory customers, announced today it will be previewing its FDA 510(k) cleared NeuMoDx™ 288 Molecular System during the 70th AACC Annual Scientific Meeting and Clinical Lab Expo to be held in Chicago, IL July 29th- August 2, 2018. NeuMoDx™...